Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Univariate analysis identified that the risk factors for CHE were Child: Pugh score ≥ 8 (odds ratio [OR] 2.22, 95% CI 1.01 to 4.89, p < 0.047); ALBI score ≥ −1.8 (OR 2.98, 95% CI 1.20 to 7.42, p = 0.019); PT < 65% (OR 3.11, 95% CI 1.18 to 8.18, p = 0.022); albumin < 3.1 g/dL (OR 4.73, 95% CI 1.55 to 14.5, p < 0.00); cholinesterase < 179 U/L (OR 2.13, 95% CI 1.04 to 4.35, p = 0.038); branched-chain amino acid to tyrosine ratio (BTR) < 3.8 (OR 2.5, 95% CI 1.17 to 5.34, p = 0.018); zinc < 74 μg/dL (OR 5.10, 95% CI 2.35 to 11.1, p < 0.001); 25-hydroxyvitamin D < 16.5 ng/mL (OR 2.52, 95% CI 1.11 to 5.69, p = 0.027); and type IV collagen 7S ≥ 8.8 ng/mL (OR 3.24, 95% CI 1.52 to 6.90, p = 0.0023).
Source: 2.2. Risk Factors for CHE in Patients with Cirrhosis. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In the off state, the participants were instructed to identify the color of the solid-colored bars as immediately as possible.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis
Study design awaiting verification · International Journal of Molecular Sciences · 2025
Original publication title
Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis
© 2025 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Covert hepatic encephalopathy (CHE) can worsen the quality of life and prognosis of patients with cirrhosis. We analyzed the risk factors of CHE and identified patients at high risk for overt hepatic encephalopathy (HE) who would benefit from therapeutic interventions. We included 145 patients without a history of or treatment for overt HE. Patients were divided into the CHE and no-CHE groups (n = 91 and 54, respectively). CHE had a score above the age-based cutoff value of one of the neuropsychological tests, such as the Stroop and number connection tests.
CHE prevalence was 62.8% (n = 91). Compared with the no-CHE group, the CHE group had significantly lower serum zinc and albumin levels. Multiple logistic regression analysis identified serum zinc levels at a cutoff value of 74 µg/dL. Subclinical zinc deficiency showed a diagnostic performance of 55.6% sensitivity and 81.5% specificity for CHE. Blood ammonia levels and liver functional reserves were not predictive of CHE. Compared with patients with zinc levels < 74 µg/dL (n = 102), those with ≥74 µg/dL (n = 43) had significantly lower CHE prevalence and better hepatic functional reserve.
Subclinical zinc deficiency was associated with CHE occurrence in patients with cirrhosis without a history of or treatment for overt HE. Measurement of zinc levels facilitates early detection of CHE by neuropsychological testing.
Authors’ abstract
Covert hepatic encephalopathy (CHE) can worsen the quality of life and prognosis of patients with cirrhosis. We analyzed the risk factors of CHE and identified patients at high risk for overt hepatic encephalopathy (HE) who would benefit from therapeutic interventions. We included 145 patients without a history of or treatment for overt HE. Patients were divided into the CHE and no-CHE groups (n = 91 and 54, respectively). CHE had a score above the age-based cutoff value of one of the neuropsychological tests, such as the Stroop and number connection tests.
CHE prevalence was 62.8% (n = 91). Compared with the no-CHE group, the CHE group had significantly lower serum zinc and albumin levels. Multiple logistic regression analysis identified serum zinc levels at a cutoff value of 74 µg/dL. Subclinical zinc deficiency showed a diagnostic performance of 55.6% sensitivity and 81.5% specificity for CHE. Blood ammonia levels and liver functional reserves were not predictive of CHE. Compared with patients with zinc levels < 74 µg/dL (n = 102), those with ≥74 µg/dL (n = 43) had significantly lower CHE prevalence and better hepatic functional reserve.
Subclinical zinc deficiency was associated with CHE occurrence in patients with cirrhosis without a history of or treatment for overt HE. Measurement of zinc levels facilitates early detection of CHE by neuropsychological testing.
Publication and source details
Original title: Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis
Takuya Matsuda; Tadashi Namisaki; Akihiko Shibamoto; Shohei Asada; Fumimasa Tomooka; Takahiro Kubo; Aritoshi Koizumi; Misako Tanaka; Satoshi Iwai; Takashi Inoue; Yuki Tsuji; Yukihisa Fujinaga; Norihisa Nishimura; Shinya Sato; Koh Kitagawa; Kosuke Kaji; Akira Mitoro; Kiyoshi Asada; Hiroaki Takaya; Ryuichi Noguchi; Takemi Akahane; Hitoshi Yoshiji
International Journal of Molecular Sciences · 2025
* Correspondence: tadashin@naramed-u.ac.jp; Tel.: +81-744-22-3051© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Japan Agency for Medical Research and Development Sciences Research23HC2001This study was partially supported by a grant-in-aid for research on hepatitis from the Japan Agency for Medical Research and Development Sciences Research Grant ID: 23HC2001.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:30:03.240278+00:00
DOI: 10.3390/ijms26094184 · PMC12071699